Intermune's 'minor improvement' gets $25k-a-year price in France
This article was originally published in Scrip
Executive Summary
Intermune is "very, very pleased" with its French price for its orphan drug Esbriet (pirfenidone) for mild to moderate idiopathic pulmonary fibrosis. CEPS, France's pricing committee has approved an ex-factory price of €25,000 per patient per year, which is on a par with the price of Actelion's Tracleer (bosentan). It is also higher than prices approved for Novartis' Gilenya and Elan/Biogen's Tysabri (natalizumab), both for MS, €22,700 and €23,500 respectively.